Advertisement
Advertisement
INTS
Intensity Therapeutics, Inc. Common stock
4.01
USDSponsored
-0.01
-0.25%
Sep 22, 15:59 UTC -4
Closed
After-Market
4.05
+0.04
+1.00%
INTS Earnings Reports
Positive Surprise Ratio
INTS beat 7 of 13 last estimates.
54%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Intensity Therapeutics, Inc. Common stock earnings per share and revenue
On Aug 11, 2026, INTS reported earnings of -1.11 USD per share (EPS) for Q2 26, missing the estimate of -0.89 USD, resulting in a -24.72% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -2.10% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
Alzamend Neuro, Inc. Common Stock
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.57
Actual
-$0.68
Surprise
-19.05%
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
>+10,000.00%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
Anixa Biosciences, Inc.
Report Date
Sep 09, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+8.78%
FAQ
What were Intensity Therapeutics, Inc. Common stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Intensity Therapeutics, Inc. Common stock reported EPS of -$1.11, missing estimates by -24.72%, and revenue of $0.00, 0% as expectations.
How did the market react to Intensity Therapeutics, Inc. Common stock's Q2 2026 earnings?
The stock price moved down -2.1%, changed from $4.29 before the earnings release to $4.20 the day after.
When is Intensity Therapeutics, Inc. Common stock expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Intensity Therapeutics, Inc. Common stock's next earnings report?
Based on --
analysts, Intensity Therapeutics, Inc. Common stock is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.